Skip to Content

'
Michael W. Bevers, M.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Gynecologic Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Michael W. Bevers, Professor in the Department of Gynecologic Oncology and Director of the Gynecologic Oncology Outreach Program since 2008, has been named the September 2006 Educator of the Month.  Since arriving at M.D. Anderson in 1994, Dr. Bevers has been instrumental in both education of young physicians and treatment of gynecologic cancers at several institutions in the Houston area.  Specifically, he has been an instructor for two Professional Education for Prevention and Early Detection courses, a Department of Surgical Oncology course, and a Medical Oncology Review Course on topics related to gynecologic oncology at M.D. Anderson; a course on surgical complications in the Departments of Obstetrics and Gynecology at The University of Texas Health Science Center at Houston; a course on endometrial cancer at Baylor College of Medicine; and a course on pelvic surgery and anatomy at The University of Texas Medical School at Houston.  In addition, Dr. Bevers led a Novartis Preceptorship Lecture Series on treatment of ovarian cancer at M.D. Anderson in 2000 and was a Co-Chairman of the Early Detection of Women's Cancers - Partnering with the Women's Health Community meeting at M.D. Anderson in 2005.  On the treatment side, Dr. Bevers has been a prime mover in providing gynecologic oncology services in Houston as Director of the Gynecologic Oncology Outreach Program.  This program, which began with the establishment of outreach relationships between M.D. Anderson and six other hospitals in the community, greatly expanding the diagnostic and treatment options for patients with gynecologic cancers.  Dr. Bevers was honored for his educational work with the Association of Professors of Gynecologiy and Obstetrics Excellence in Teaching Award and in 2003 with the M.D. Anderson Outstanding Educator Award and the Baylor College of Medicine Gynecologic Exceptional Teaching Award.  Furthermore, he has been on the Best Doctors in America list every year since 2003, was named to the America's Top Obstetricians and Gynecologists list in 2004, and was named a Texas Super-Doc from 2004 to 2008.

Dr. Bevers received his M.D. degree from The University of Texas Health Science Center at San Antonio in 1990.  After completing an internship in 1991 and residency in Obstetrics and Gynecology in 1994 at Parkland Memorial Hospital at The University of Texas Southwestern Medical School at Dallas, Dr. Bevers came to M.D. Anderson as a Fellow in Gynecologic Oncology and a Junior Faculty Associate in the Department of Gynecologic Oncology.  In 1996, Dr. Bevers was promoted to Assistant Professor of Gynecologic Oncology and named Director of Gynecologic Oncology Medical Information Systems and Coordinator of the St. Luke's Gynecologic Oncology Outreach Pilot.  After being named Director of the Gynecologic Oncology Outreach Program in 2001, Dr. Bevers was promoted to Associate Professor in the Department of Gynecologic Oncology in 2002.  Dr. Bevers has been a member of the M.D. Anderson Fellowship Planning Committee since 2003 and the M.D. Anderson Surgery Working Group since 2005.  He is also a member of the active, provisional, or consulting staff of seven local hospitals.  In addition to his numerous clinical and educational duties, Dr. Bevers has served on the Government Affairs Committee of the Society of Clinical Gynecologists since 1997 and as Editor of the Handbook of Gynecologic Oncology since 1999.  During his time at M.D. Anderson, Dr. Bevers has written numerous articles published in refereed journals, abstracts, and book chapters on an array of topics pertaining to gynecologic cancer.

Office Address

The University of Texas MD Anderson Cancer Center
Regional Care Center Katy
19770 Kingsland Blvd
Unit Number: 2052
Houston, TX 77094
Phone: 713-563-9600
Fax: 281-646-4320

Education & Training

Degree-Granting Education

1990 The University of Texas Health Science Center, San Antonio, TX, MD, Medicine
1985 Texas Wesleyan University, Fort Worth, TX, BS, Biology

Postgraduate Training

7/1994-6/1996 Clinical Fellowship, Gynecologic Oncology, The University of Texas MD Anderson Hospital Cancer Center, Houston, TX, Dr. Mitchell Morris
7/1991-6/1994 Clinical Residency, Obstetrics and Gynecology, The University of Texas Southwestern Medical School, Dallas, TX, Dr. Alvin Brekken
7/1990-6/1991 Clinical Internship, The University of Texas Southwestern Medical School, Dallas, TX, Dr. Alvin Brekken

Experience/Service

Administrative Appointments/Responsibilities

Coordinator, Department of Gynecologic Oncology Monthly Morbidity and Mortality Conference, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011-present
Director, Gynecologic Oncology Outreach Program, Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2001-present

Other Appointments/Responsibilities

Member, Cancer Committee, St. Luke's Episcopal Hospital, Houston, TX, 1/1998-present

Institutional Committee Activities

Member, CancerWISE Community Speakers Bureau, 1996-present

Honors and Awards

2013-2014 Best Doctors in America
2006 APGO Exellence in Teaching Award
2004-2012 Educator of the Month, October, The University of Texas M.D. Anderson Cancer Center
2004-2011 Texas Super-Doc
2004 Americas Top Obstetricians and Gynecologists
2003-2012 Best Doctors in America
2003 Gynecologic Exceptional Teaching Award, Baylor College of Medicine
2003 Outstanding Educator, The University of Texas M.D. Anderson Cancer Center
1994 Outstanding Resident Teaching Award, The University of Texas Southwestern Medical School, Parkland Memorial Hospital
1994 Texas Residents Research Symposium Award for Best Resident Research Project, The University of Texas Southwestern Medical School, Parkland Memorial Hospital

Professional Memberships

American College of Obstetrics and Gynecologists
Member, 1998-present
American Society of Clinical Oncologists
Member, 2001-present
Felix Rutledge Society
Member, 1996-present
Harris County Medical Society
Member, 1994-present
Houston Gynecological & Obstetrical Society
Member, 1996-present
M.D. Anderson Associates
Member, 1994-present
Society of Gynecologic Oncologists
Member, 2001-present
Texas Association of Obstetrics and Gynecologists
Member, 1996-present
Texas Medical Association
Member, 1994-present
Texas Medical Foundation
Member, 1994-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Burzawa JK, Schmeler KM, Soliman PT, Meyer LA, Bevers MW, Pustilnik TL, Anderson ML, Ramondetta LM, Tortolero-Luna G, Urbauer DL, Chang S, Gershenson DM, Brown J, Lu KH. Prospective evaluation of insulin resistance among endometrial cancer patients. Am J Obstet Gynecol 204(4):355.e1-7, 4/2011. e-Pub 2/16/2011. PMID: 21324431.
2. Jones KL, Saucier JM, Sun CC, Bevers MW, Ramondetta LM, Brown J, Smith JA. Comparison of chemotherapy education and patient preferences in community versus academic gynecology oncology clinics. J Oncol Pharm Pract 14(1):31-6, 2008 March, 3/2008.
3. Ramirez PT, Frumovitz M, Dos Reis R, Milam MR, Bevers MW, Levenback CF, Coleman RL. Modified uterine manipulator and vaginal rings for total laparoscopic radical hysterectomy. Int J Gynecol Cancer 18(3):571-5, 2008 May-June, 2008.
4. Frumovitz M, Dos Reis R, Sun CC, Milam MR, Bevers MW, Brown J, Slomvitz BM, Ramirez PT. Comparison of total laparoscopic and abdominal radical hysterectomy for patients with early-stage cervical cancer. Obstet Gynecol 110(1):96-102, 2007.
5. Said HK, Bevers M, Butler CE. Reconstruction of the pelvic floor and perineum with human acellular dermal matrix and thigh flaps following pelvic exenteration. Gynecol Oncol 107(3):578-82, 2007 Dec, 2007.
6. Slomovitz BM, Ramirez PT, Frumovitz M, Soliman PT, Bevers M, Coleman RL, Levenback C. Electrothermal bipolar coagulation for pelvic exenterations. Gynecol Oncol 102:534-6, 9/2006. PMID: 16483643.
7. de Moor JS, de Moor CA, Basen-Engquist K, Kudelka A, Bevers MW, Cohen L. Optimism, distress, health-related quality of life, and change in cancer antigen 125 among patients with ovarian cancer undergoing chemotherapy. Psychosom Med 68(4):555-62, 7/2006. PMID: 16868264.
8. Stevens TA, Brown J, Zander DS, Bevers MW, Gershenson DM, Ramondetta LM. Adult granulosa cell tumors of the ovary in two first-degree relatives. Gynecol Oncol 98(3):502-5, 9/2005. PMID: 15992917.
9. Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT, Rubenstein EB. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13(4):219-27, 4/2005. PMID: 15538640.
10. Ramirez PT, Sun CC, Vidal CI, Schimp V, Slomovitz BM, Bevers MW, Bodurka DC. Outcomes of hysteroscopy and hysterectomy in breast cancer patients. Cancer Ther 3:147-152, 2005.
11. Donato ML, Aleman A, Champlin RE, Saliba RM, Wharton JT, Burke TW, Bodurka DC, Bevers MW, Levenback CF, Wolf JK, Bast RC, Freedman RS, Ippoliti C, Brewer M, Gajewski JL, Gershenson DM. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 33(12):1219-24, 6/2004. PMID: 15122311.
12. Frumovitz M, Slomovitz BM, Singh DK, Broaddus RR, Abrams J, Sun CC, Bevers M, Bodurka DC. Frozen section analyses as predictors of lymphatic spread in patients with early stage uterine cancer. J Amer Coll Surg 199:388-393, 2004.
13. Ramondetta LM, Burke TW, Jhingran A, Schmandt R, Bevers MW, Wolf JK, Levenback CF, Broaddus R. A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed mullerian tumors with evaluation of potential molecular targets. Gynecol Oncol 90(3):529-36, 9/2003. PMID: 13678720.
14. Ramirez PT, Modesitt SC, Morris M, Edwards CL, Bevers MW, Wharton JT, Wolf JK. Functional outcomes and complications of continent urinary diversions in patients with gynecologic malignancies. Gynecol Oncol 85(2):285-91, 5/2002. PMID: 11972389.
15. Donato ML, Gershenson DM, Wharton JT, Ippoliti CM, Aleman AS, Bodurka-Bevers D, Bevers MW, Burke TW, Levenback CF, Wolf JK, Freedman RS, Bast RC, Jr, Gajewski JL, Champlin RE. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. Gynecol Oncol 82(3):420-6, 9/2001. PMID: 11520135.
16. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 19(14):3422-33, 7/2001. PMID: 11454891.
17. Levenback C, Coleman R, Burke TW, Bevers M, Bodurka-Bevers D, Wolf JK, Gershenson DM. Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer. Gynecol Oncol 83(2):276-281, 2001.
18. Ramondetta L, Burke TW, Levenback C, Bevers MW, Bodurka-Bevers D, Gershenson DM. Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol Oncol 82(1):156-161, 2001.
19. Bodurka-Bevers D, Morris M, Eifel PJ, Levenback C, Bevers MW, Lucas KR, Wharton JT. Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol 78(2):187-93, 8/2000. PMID: 10926801.
20. Parker LP, Parker JR, Bodurka-Bevers D, Deavers M, Bevers MW, Shen-Gunther J, Gershenson DM. Paget's disease of the vulva: pathology, pattern of involvement, and prognosis. Gynecol Oncol 77(1):183-9, 4/2000. PMID: 10739709.
21. Donato ML, Gershenson D, Ippoliti C, Wharton JT, Bast RC, Aleman A, Anderlini P, Gajewski JG, Giralt S, Molldrem J, Ueno N, Lauppe J, Korbling M, Boyer J, Bodurka-Bevers D, Bevers M, Burke T, Freedman R, Levenback C, Wolf J, Champlin RE. High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplant 25(11):1137-1140, 2000.
22. Verschraegen CF, Levenback C, Vincent M, Wolf J, Bevers M, Loyer E, Kudelka AP, Kavanagh JJ. Phase II study of intravenous Dx-891f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan. Ann N Y Acad Sci 922:349-351, 2000.
23. Moon C, Verschraegen CF, Bevers M, Freedman R, Kudelka AP, Kavanagh JJ. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity. Anti-Cancer Drugs 11(7):565-568, 2000.
24. Lin PS, Gershenson DM, Bevers MW, Lucas KR, Burke TW, Silva EG. The current status of surgical staging of ovarian serous borderline tumors. Cancer 85(4):905-11, 2/1999. PMID: 10091769.

Abstracts

1. Frumovitz M, Slomovitz BM, Broaddus RR, Abrams J, Sun CC, Bevers M, Bodurka DC. Endometrial cancer: To stage or not to stage, part II. Gynecol Oncol 92(1):487, 2004.
2. Bodurka DC, Sun CC, Weaver CB, Jennings J, Melancon CH, Bevers MW, Wolf JK, Ramirez PT, Gershenson DM, Lairson DR. Ovarian cancer (OV CA): The cost of caregiving. Gynecol Oncol 92(1):456, 2004.
3. Ramirez PT, Vidal CI, Schimp VL, Sun CC, Slomovitz BM, Bevers MW, Bodurka DC. Indications and outcomes of hysteroscopy and hysterectomy in breast cancer patients. Gynecol Oncol 88(2):216, 2003.
4. Bodurka DC, Frumovitz M, Sun CC, Ramirez PT, Bevers MW, Gershenson DM. Laparoscopy for probable ovarian cancer: less may not be more. Gynecol Oncol 88(2):244, 2003.
5. Ramondetta LM, Broaddus R, Wolf JK, Levenback C, Bevers M, Burke TW. A phase II trial of cisplatin and ifosfamide/mesna in patients with advanced or recurrent uterine mixed Mullerian tumors. Proceedings of the American Society of Clinical Oncology 21:213a, 2002.
6. Donato ML, Aleman AS, Gershenson DM, Wharton JT, Bast JrRC, Burke TW, Bodurka Bevers D, Bevers MW, Levenback CF, Wolf JK, Freedman RS, Cooke S, Ippoliti C, Brewer M, Gajewski JL, Champlin RE. Long term results of 102 patients with advanced ovarian cancer treated with high-dose chemotherapy. Proceedings of the American Society of Clinical Oncology 20:204a, 2001.
7. Donato ML, Gershenson D, Ippoliti C, Wharton JT, Bast RC Jr, Aleman A, Anderlini P, Gajewski JG, Giralt S, Molldrem J, Ueno N, Lauppe J, Korbling M, Boyer J, Bodurka-Bevers D, Bevers M, Burke T, Freedman R, Levenback C, Wolf J, Champlin RE. High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplant 25:1137-1140, 2000.
8. Levenback C, Coleman RL, Burke TW, Bevers MW, Bodurka-Bevers D, Wolf JK, Gershenson DM. Intraoperative lymphatic mapping of the vulva with blue dye. Gynecol Oncol 76(2):234, 2000.
9. Verschraegen CF, Levenback C, Vincent M, Wolf J, Bevers M, Loyer E, Kudelka AP, Kavanagh JJ. Phase II study of intravenous Dx-891f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan. Proceedings of the American Society of Clinical Oncology 16a:1550, 2000.
10. Parker LP, Parker JR, Deavers M, Bodurka-Bevers D, Bevers MW, Price JR, Gershenson DM. Prognostic factors and role of immunohistochemistry in Paget’s disease of the vulva. Cancer J Sci Med 6:112, 2000.
11. Bodurka-Bevers D, Lu K, Wolf JK, Bevers MW, Branham D, Silva EG, Gershenson DM. The clinical course of low-grade serous carcinoma of the ovary. Gynecol Oncol 76(2):255, 2000.
12. Donato ML, Gershenson DM, Ippoliti C, Wharton JT, Bevers MW, Bodurka-Bevers DC, Levenback CF, Wolf JK, Freedman RS, Bast RC Jr, Burke TW, Champlin RE. Topotecan in combination with cyclophosphamide and melphalan for stem cell transplantation: Results of a large phase I trial in advanced ovarian cancer. Proceedings of the American Society of Clinical Oncology 19:50a, 2000.
13. Bodurka-Bevers D, Basen-Engquist KM, Fitzgerald MA, Bevers MW, Wolf JK, Levenback C, Gershenson DM. Depression may worsen quality of life in patients with epithelial ovarian cancer. Gynecol Oncol 72:449, 1999.
14. Dalrymple JL, Levenback C, Wolf JK, Bevers DB, Bevers MW, Gershenson DM. End of life care for inpatient gynecologic oncology patients. Proceedings of the American Society of Clinical Oncology 18:578a, 1999.
15. Donato M, Gershenson D, Wharton JT, Aleman A, Ippoliti C, Bodurka D, Levenback C, Bevers M, Wolf J, Freedman R, Gajweski J, Bast R, Champlin RE. Phase I study of high-dose topotecan and alkylating agents for advanced ovariancancer. Proceedings of the American Society of Clinical Oncology 18:44a, 1999.
16. Parker LP, Parker JR, Bevers DB, Deavers M, Price JR, Atkinson EN, Bevers MW, Gershenson DM. Risk factors for recurrence and poor prognostic factors of patients with Paget's disease of the vulva. Gynecol Oncol 72:463, 1999.
17. Basen-Engquist K, Pentz R, DeJesus Y, Greisinger A, Anderlick M, Smith T, Gershenson D, Wolf JK, Bodurka D, Bevers M, Levenback C. Advance Care Planning for the End of Life. J Cancer Education 13(3):31, 1998.
18. Lin PS, Gershenson DM, Bevers MW, Lucas KR, Silva EG. Current surgical staging of serous borderline ovarian tumors. ACOG Abstract Book:80, 1998.
19. Verschraegen C, Kudelka AP, Bevers M, Edwards CL, Freedman RS, Steger M, Wharton JT, Kavanagh JJ. Endocrine response following subcutaneous injections of Cetro-relix in postmenopausal women. Proc of the AACR Meeting 39:3270, 1998.
20. Kudelka AP, Kavanagh JJ, Freedman RS, Wolf JK, Gershenson DM, Bevers MW, Huang L, Lopez-Berenstein G, Hortobagyi GN. Phase I E1A gene therapy in patients with advanced breast and ovarian cancer. Proc of the AACR Meeting 39:2458, 1998.
21. Ueno NT, Hung MC, Zhang S, Xia W, Willey JS, Warner DL, Payne JY, Nandagiri R, Aldridge R, De Jager RL, Tucker S, Putnam JB, Sneige N, Katz RL, Spohn WH, Bast RC, Holmes FA, Ibrahim NK, Theriault RL, Rahman ZU, Valero V, Kudelka AP, Kavanagh JJ, Freedman RS, Wolf JK, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hortobagyi GN. Phase I E1A gene therapy in patients with advanced breast and ovarian cancer. Proceedings of AACR Meeting 39:2458, 1998.
22. Donato M, Gershenson D, Wharton JT, Ippoliti C, Bodurka D, Levenback C, Gajweski J, Bevers M, Freedman R, Edwards C, Wolf J Champlin RE. Phase I study of high-dose alkylating agents and topotecan for advanced ovarian cancer. Proceedings of the American Society of Clinical Oncology 17:75a, 1998.
23. Brewer MA, Bodurka DC, Bevers M, Gershenson DM, Burke TM, Wolf JK. Postoperative nasogastric intubation in gynecologic oncology patients. Gynecol Oncol 68:126, 1998.
24. Bodurka DC, Levenback C, Bevers MW, Munkarah AR, Burke TW, Price K, Gershenson DM. Outcomes of gynecologic oncology patients with adult respiratory distress syndrome. Gynecol Oncol 64:160, 1997.
25. Vadan-Raj S, Verschraegan C, McGarry L, Bueso-Ramos C, Kudelka A, Freedman R, Edwards C, Bevers M, Levenback C, Gershenson D, Jones D, Yang T, Bast RC, Kavanagh JT. Recombinant human thrombocytopenia (rhTPO) attenuates high-dose carboplatin (C)-induced thrombocytopenia in patients with gynecologic oncology. American Society of Hematology 39th Annual Meeting 90, 1997.

Book Chapters

1. Bevers MW, Bodurka-Bevers DC, Wolf JK. Gynecologic Cancers. In: The M. D. Anderson Surgical Oncology Handbook; Third Edition. Lippincott Williams & Wilkins, 445-490, 2003.
2. Bodurka-Bevers D, Bevers MW, Sukumaran A. Critical Care. In: Handbook of Gynecologic Oncology. Chapter 5. Martin Dunitz Ltd, 87-109, 2000.
3. Bodurka-Bevers D, Follen M, Bevers MW. Preinvasive disease of the lower female genital tract. In: Handbook of Gynecologic Oncology. Chapter 10. Martin Dunitz Ltd, 197-205, 2000.
4. Bevers MW, Bodurka-Bevers DC, Wolf JK. Gynecologic Cancers. In: The M. D. Anderson Surgical Oncology Handbook; Second Edition. Lippincott Williams & Wilkins, 377-424, 1998.

Books (edited and written)

1. Barakat RR, Bevers MW, Gershenson DM, Hoskins WJ (eds). Handbook of Gynecologic Oncology. Martin Dunitz Ltd, 2002.
2. Barakat RR, Bevers MW, Gershenson DM, Hoskins WJ (eds). Handbook of Gynecologic Oncology. Martin Dunitz Ltd, 2000.

Manuals, Teaching Aids, Other Teaching Publications

1. Bevers MW. Endoscopy, Gastrostomy, and Related Procedures. 2, 98. 6, 2001.
2. The University of Texas M. D. Anderson Gynecologic Oncology Handbook. 1996.

Last updated: 9/6/2016